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Background. Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing,
is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The efficacy
of dalbavancin for treatment of skin and skin structure infections (SSSIs) was demonstrated in a phase 2 study.
Methods. In a phase 3 noninferiority study, patients with complicated SSSIs, including infections known or
suspected to involve MRSA, were randomized (ratio, 2:1) in a double-blind manner to receive dalbavancin (1000
mg given intravenously on day 1 and 500 mg given intravenously on day 8) or linezolid (600 mg given intravenously
or intravenously/orally every 12 h for 14 days). Efficacy was assessed by determining clinical and microbiological
responses at the end of therapy and at the test-of-cure visit. Relapses were identified by additional follow-up ∼1
month later.
Results. MRSA was identified in 51% of patients from whom a pathogen was isolated at baseline. Dalbavancin
and linezolid demonstrated comparable clinical efficacy in the clinically evaluable population at the test-of-cure
visit (88.9% and 91.2% success, respectively). The rate of clinical success at the end of therapy was 190% in both
arms. Less than 1.0% of patients in either treatment arm experienced relapse after the test-of-cure visit. Both
treatments yielded successful microbiological response in excess of 85% among microbiologically evaluable patients
at end of therapy and at the test-of-cure visit for all pathogens combined, for all S. aureus strains, and for MRSA.
Gastrointestinal symptoms were among the most common adverse events in both arms. A higher proportion of
patients in the linezolid arm reported adverse events that were judged by the investigator to be probably/possibly
related to treatment (dalbavancin arm, 25.4% of subjects; linezolid arm, 32.2% of subjects).
Conclusions. Two doses of dalbavancin (1000 mg given on day 1 followed by 500 mg given on day 8) were
as well tolerated and as effective as linezolid given twice daily for 14 days for the treatment of patients with
complicated SSSI, including those infected with MRSA.
Dalbavancin is a novel, semisynthetic lipoglycopeptide
antibacterial with a pharmacokinetic profile that allows
weekly dosing. It has potent in vitro activity against
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gram-positive bacteria, including methicillin-resistant
Staphylococcus aureus (MRSA), and it is superior to
most of the other antibiotics used to treat gram-positive
bacterial infections, including vancomycin [1, 2]. In
addition, dalbavancin has demonstrated superior in
vivo activity against infection due to MRSA and other
bacteria in animal infection models [3–5]. Its spectrum
of activity suggests that dalbavancin has the potential
to be useful for treatment of skin and skin structure
infections (SSSIs). Gram-positive bacteria—in partic-
ular, S. aureus and Streptococcus pyogenes—are among
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S. aureus accounting for more than one-half of the isolates [6],
and the prevalence of MRSA as a pathogen in institutional and
community settings [7].
The half-life of dalbavancin in humans (∼8.5 days) allows
weekly administration of the drug, with therapeutic concen-
trations in plasma maintained for the entire 7-day period be-
tween doses. In a phase 2 investigation of dalbavancin treatment
for SSSI, a 2-dose regimen (a 1000-mg dose given on day 1
followed by a 500-mg dose given on day 8) appeared to be well
tolerated and to be more effective for the treatment of SSSI
due to gram-positive bacteria, compared with either a single-
dose dalbavancin regimen (1100 mg given on day 1) or the
investigator-chosen standard of care [8]. The goal of the present
study was to demonstrate the safety and efficacy of dalbavancin
for the treatment of patients with complicated SSSI, compared
with linezolid, an antibacterial used for treatment of such
infections.
PATIENTS, MATERIALS, AND METHODS
Study population. Participants consisted of adults with sus-
pected or confirmed SSSI due to gram-positive pathogens that
warranted initial parenteral therapy. Complicated SSSI was de-
fined as infection that involved deeper soft tissue or that re-
quired significant surgical intervention (e.g., major abscesses,
major burns, traumatic or surgical wound infections, and deep
skin/skin-structure infection, such as extensive/ulcerating cel-
lulitis) or as an SSSI known or suspected to be caused by MRSA.
Patients were also required to have at least 2 local signs and/
or symptoms of complicated SSSI (i.e., drainage/discharge, er-
ythema, fluctuance, heat/localized warmth, pain/tenderness to
palpation, or swelling/induration) and at least 1 sign of systemic
infection or of another complicating factor, such that the pa-
tient required parenteral therapy. Patients known or suspected
to have osteomyelitis or septic arthritis, those with infections
expected to require 12 surgical interventions during the study,
and those with concomitant conditions requiring antimicrobial
therapy that would interfere with the evaluability of the con-
dition under study were excluded from participation.
Study design and treatments. This randomized, double-
blind, study enrolled patients at 65 centers in 7 countries
(United States, Latvia, Lithuania, Canada, the United Kingdom,
Estonia, and Germany) during the period of January 2003
through May 2004. Before the study was initiated, the health
care centers obtained approval for participation from an in-
stitutional review board or independent ethics committee. All
patients provided informed consent before undergoing any
study procedures.
An unblinded third party who was otherwise uninvolved in
the study (e.g., a study pharmacist) called an interactive voice-
activated randomization system to obtain treatment assign-
ments. Patients were randomized to treatment arms in a 2:1
ratio to receive dalbavancin or linezolid. Patients in the dal-
bavancin arm received a 1000-mg dose on day 1, followed by
a 500-mg dose on day 8, with a possible switch to oral placebo
if criteria for a switch from intravenous to oral therapy were
met (i.e., defervescence or clinical improvement at the SSSI site
after 24 h of parenteral therapy). Patients randomized to the
linezolid arm received 600 mg of linezolid intravenously every
12 h, with a possible switch to orally administered linezolid
(600 mg every 12 h) after at least 24 h of intravenous therapy.
For both treatment arms, the total course of therapy (intra-
venous and oral) was 14 days. Each dalbavancin dose was de-
fined as 7 days of therapy.
For blinding purposes, after the initial dalbavancin dose was
administered, patients in the dalbavancin arm received placebo
infusions of 5% dextrose for infusion or normal saline every
12 h until the treatment was switched to oral placebo. All
patients (regardless of treatment assignment) received an in-
travenous infusion of study medication on day 8. Patients in
the dalbavancin arm received 500 mg of intravenous dalba-
vancin (plus oral placebo if they had already switched to oral
therapy). Patients in the linezolid arm either continued to re-
ceive intravenous linezolid or received an intravenous placebo
infusion on day 8, plus the oral linezolid regimen, if they had
already switched to oral therapy.
Empirical use of aztreonam and/or metronidazole was per-
mitted for suspected mixed infections due to gram-negative
pathogens. These treatments were discontinued if the etiology
was determined to be strictly gram-positive pathogens. Use of
any other antibacterial was prohibited.
Clinical and microbiological evaluations. Patients were as-
sessed at baseline and on the day of the switch from intravenous
to oral therapy, in addition to the following study visits: day
4, day 8, the end-of-therapy (EOT) visit (within 3 days after
completion of treatment with the study medication), and the
test-of-cure (TOC) visit ( days after completion of treat-14  2
ment with the study medication). Signs and symptoms of SSSIs
were recorded at each visit. The investigator assessed patients
as having an outcome of clinical success, clinical failure, or
indeterminate at the EOT and TOC visits on the basis of pre-
sentation of the SSSI. Samples for SSSI cultures were obtained
at baseline, and cultures were repeated at each study visit if
clinically warranted or if the patient was determined to have
experienced treatment failure. If appropriate, blood samples
were obtained for culture at baseline, and cultures were repeated
until the results were negative if they had been positive initially.
Adverse events, concomitant medications, and vital signs were
recorded at each visit. Blood samples were obtained for eval-
uation of hematology, and clinical chemistry parameters were
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Table 1. Study population and reasons for exclusion in a study of once-weekly dal-
bavancin versus twice-daily linezolid therapy for the treatment of complicated skin and
skin structure infections (SSSIs).
Variable






All 571 (100) 283 (100)
Excluded patients
Received prohibited antibiotica 55 (10) 28 (10)
Clinical response of indeterminate at TOC visit 38 (7) 20 (7)
Received !3 days of study medication, including placebob 24 (4) 2 (1)
Otherc 20 (4) 7 (2)
Patients who were clinically evaluable at the TOC visit 434 (76) 226 (80)
Microbiological intent-to-treat population 358 (63) 192 (68)
Patients who were microbiologically evaluable at the TOC visit 277 (77)d 152 (79)d
NOTE. TOC, test of cure.
a Received 124 h of another systemic antibacterial therapy with documented activity against the caus-
ative organism within 7 days prior to receipt of the first dose of study medication through the TOC visit
or topical antibacterials for SSSI during the study, unless antibiotic was given for clinical failure.
b To determine clinical evaluability in a blinded manner, all patients were required to receive 72 h of
study medication (active or active/placebo), irrespective of treatment assignment. Patients who received
!72 h of treatment were assigned an indeterminate clinical response.
c Includes TOC visits outside the protocol-defined window, violations of inclusion/exclusion criteria that
affected efficacy, and unanticipated surgical intervention for SSSI (clinical successes only).
d Denominator for percentage calculation is the no. of patients in the microbiological intent-to-treat
population.
In addition, patients who were determined to have had clinical
success at the TOC visit were contacted ∼1 month after the
14-day treatment period (day days) for completion of39  3
a late follow-up questionnaire. By phone interview, site per-
sonnel completed a standardized questionnaire of the patient’s
responses to inquiries regarding visits to a health care provider
for the SSSI after the TOC visit, the status of SSSI signs and/
or symptoms, the presence of fever, the occurrence of serious
adverse events, and receipt of antibacterials for an SSSI after
the TOC visit.
Statistical analysis. Efficacy was determined by evaluation
of clinical and microbiological responses, both separately and
combined, at the EOT and TOC visits. The primary end point
was clinical success at the TOC visit. A successful clinical re-
sponse was one in which signs and symptoms of SSSI had
improved such that no further antibacterial therapy was war-
ranted. A response of failure was assigned to patients for whom
the SSSI had not improved or had worsened or who required
additional antibacterials for the SSSI. Patients who received !72
h of study medication or who did not present for evaluation
were considered to have indeterminate results. Relapse was de-
fined as receipt of antibacterials for the SSSI after the TOC
visit. The presence or absence of baseline gram-positive path-
ogens at the EOT and TOC visits was used for programmatic
determination of microbiological response for each patient and
pathogen. Microbiological response was presumed on the basis
of clinical response if no culture results were available. Suc-
cessful microbiological response at the patient level included
eradication or presumed eradication of all baseline gram-
positive pathogens. Overall response combined clinical and mi-
crobiological response for a comprehensive assessment of
efficacy.
Four populations were prospectively identified for evaluation
of efficacy: the intent-to-treat population, the clinically eval-
uable population, the microbiological intent-to-treat popula-
tion, and microbiologically evaluable population. The intent-
to-treat population consisted of all treated patients. Clinically
evaluable patients received at least 72 h of treatment with the
blinded study medication, did not have an indeterminate clin-
ical response, and fulfilled all other protocol requirements re-
lating to concurrent use of antibacterials, surgical intervention
of the SSSI, and efficacy-related inclusion/exclusion criteria.
The microbiological intent-to-treat population was the subset
of the intent-to-treat population with a baseline gram-positive
pathogen. Microbiologically evaluable patients were patients
who were clinically evaluable and for whom there was a baseline
gram-positive pathogen. The primary analysis was a compar-
ison of the clinical success rates between treatment arms among
clinically evaluable patients at the TOC visit [9]. A 1-sided
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Table 2. Selected demographic and baseline characteristics









Male sex 353 (62) 172 (61)
Age, years
Mean  SD 47  16 46  17
Range 18–93 18–92
Ethnicity
White 390 (68) 194 (69)
Hispanic/Latino 109 (19) 45 (16)
Black 59 (10) 32 (11)
Other 13 (2) 12 (4)
SSSI history
Cause of infection
Spontaneous 286 (50) 133 (47)
Trauma 141 (25) 77 (27)
Postsurgery infection 57 (10) 31 (11)
Bite 54 (9) 18 (6)
Other 33 (6) 24 (8)
Type of infection
Major abscess 190 (33) 86 (30)
Cellulitis 157 (27) 84 (30)
Other deep soft-tissue infection 96 (17) 46 (16)
Traumatic wound infection 63 (11) 33 (12)
Surgical wound infection 47 (8) 27 (10)
Infected major burna 18 (3) 7 (2)
Medical history
Baseline hospitalization 357 (63) 182 (64)
Diabetes mellitus 139 (24) 60 (21)
Vascular disease 61 (11) 18 (6)
Use of prosthetic devices 30 (5) 10 (4)
Cancer 3 (1) 2 (1)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Burn on 20% of body surface.
Table 3. Distribution of gram-positive pathogens isolated from








Total no. of gram-positive
pathogen isolates 391 215
Staphylococcus aureus
Alla 318 (89) 174 (91)
MRSA 181 (51) 97 (51)
No. (%) of S. aureus isolates
that were MRSA 181 (57) 97 (56)
Streptococcus pyogenes 19 (5) 12 (6)
Streptococcus agalactiae 16 (4) 10 (5)
Viridans Streptococcus species 15 (4) 6 (3)
Group G Streptococcus species 10 (3) 6 (3)
Group C Streptococcus species 5 (1) 3 (2)
NOTE. Data are no. (%) of patients in the microbiological intent-to-treat
population of each treatment arm, unless otherwise indicated. MRSA, meth-
icillin-resistant S. aureus.
a Includes strains identified as MRSA.
tween dalbavancin and linezolid. Noninferiority was concluded
if the lower limit of the 1-sided 97.5% CI did not exceed
12.5%. Safety was evaluated for the intent-to-treat population
by collection and analysis of data on adverse events, clinical
laboratory test results, and vital signs.
RESULTS
Study population. Eight hundred fifty-four patients with
complicated SSSI received treatment under this protocol. Cen-
ters in North America enrolled and treated 87% of the patients.
Of the 854 treated patients, 700 (82%) were clinically evaluable
at the EOT visit, and 660 (77%) were clinically evaluable at
the TOC visit. The primary reasons for nonevaluability are
listed in table 1. The proportions of patients excluded for each
reason were similar between treatment arms, except for patients
who received !72 h of treatment, for which the proportion was
higher in the dalbavancin arm.
The treatment arms were well matched with respect to de-
mographic and baseline characteristics (table 2). The sole rel-
evant difference between groups was a significantly higher in-
cidence of vascular disease in the dalbavancin arm. Cause, type,
and presentation of SSSI were also similar between treatment
arms. Approximately one-half of the SSSIs were spontaneous
in origin; 26% resulted from trauma. Major abscesses (32%)
and cellulitis (28%) were the predominant infection types. Signs
and/or symptoms of SSSI reported at baseline for 195% of
patients included erythema, heat/localized warmth, pain/ten-
derness to palpation, and swelling/induration.
Baseline microbiological findings. Baseline cultures
yielded at least 1 gram-positive pathogen for 550 patients (64%;
the microbiological intent-to-treat population). Of these, 90%
presented with a single gram-positive pathogen. S. aureus was
predominant (89% of all patients). Of the S. aureus isolates,
278 (57%) of 492 were MRSA. Overall, 51% of patients pre-
sented with SSSI that involved MRSA. No pathogen species
other than S. aureus accounted for 16% of SSSIs in either arm
(table 3).
Clinical efficacy. Among patients who were clinically ev-
aluable at the TOC visit, 88.9% in the dalbavancin arm and
91.2% in the linezolid arm achieved clinical success. The lower
limit of the 95% CI (7.28%) was within the limit for dem-
onstration of noninferiority (12.5%) that was prospectively
defined for the primary end point. Figure 1 compares clinical
success rates and other end points at the EOT and TOC visits
in the 2 treatment arms.
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Figure 1. Summary of response end points in the evaluable populations illustrating the similarity between the dalbavancin and linezolid arms in
the percentages of patients with clinical, microbiological, and overall (combined clinical/microbiological) success at end-of-therapy (EOT) and test-of-
cure (TOC) visits.
Table 4. Evaluation of responses to a late follow-up questionnaire.
Variable








Patients eligible for late follow-up assessmenta 316 163
Response
Success
All 298 (94) 151 (93)
No visit to health care provider for SSSI after the TOC visit 282 (89) 135 (83)
Contacted health care provider after TOC visit regarding
SSSI but did not receive additional antibiotics 16 (5) 16 (10)
Failureb 2 (0.6) 1 (0.6)
Unavailable for interview 16 (5) 11 (7)
NOTE. SSSI, skin and skin structure infection; TOC, test of cure.
a Clinically evaluable patients with successful clinical response at the TOC visit.
b Patient received additional antibiotics for treatment of SSSI after the TOC visit.
of patients in each treatment arm). The clinical response of
treatment failure for these patients was carried forward to the
TOC visit. Efficacy was independent of infection type (e.g.,
major abscess and cellulitis).
Microbiological efficacy. Microbiological success at the pa-
tient level was similar between treatment arms among micro-
biologically evaluable patients at the EOT and TOC visits (figure
1). Microbiological response reflected the results for clinical
response. Documented persistence of baseline pathogens oc-
curred at the EOT visit for 8% and 7% of patients in the
dalbavancin and linezolid arms, respectively, and for 2% of
patients in either treatment arm at the TOC visit. Recurrence
of initial pathogen(s) at the TOC visit was documented for a
small percentage of patients (1% for the dalbavancin arm and
4% for the linezolid arm).
On a pathogen basis, dalbavancin and linezolid both erad-
icated at least 85% of baseline pathogens at both the EOT and
TOC visits. MRSA eradication rates at the TOC visit (eradicated
or presumed eradicated) were 91% and 89% for the dalbavan-
cin and linezolid arms, respectively. Emergence of new path-
ogens at the TOC visit (i.e., superinfection) occurred rarely
(!1% of patients in either arm).
Overall response. Overall success rates were similar be-
tween treatment arms at the EOT and TOC visits (figure 1).
Durability of response. The late follow-up assessment ap-
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Any event 25.4 32.2
Nausea 3.2 5.3
Diarrhea 2.5 5.7
Elevated blood lactate dehydrogenase level 1.9 1.8
Headache 1.9 1.8
Elevated g-glutamyltransferase level 1.9 1.4
Vomiting 1.9 1.1
Rash 1.8 1.8
Abnormal liver function test results 1.6 1.1
Elevated alanine aminotransferase level 1.2 1.8
Fungal vaginosis 0.9 1.8
Loose stools 0.4 2.1
Thrombocytopenia 0.2 2.5
NOTE. Table lists adverse events with probable or possible relationship with treat-
ment that were experienced by 2% of patients in the study.
Figure 2. Duration of adverse events related to dalbavancin and linezolid therapy in the intent-to-treat population
TOC visit. Among the 94% of eligible evaluable patients in-
terviewed, the vast majority in each treatment arm had not
contacted a health care provider regarding their SSSI after the
TOC visit (table 4). Reports of persistent or new signs/symp-
toms of SSSI were infrequent. Only 0.6% of contacted patients
in each treatment arm were considered to have experienced a
relapse on the basis of receipt of additional antibacterial therapy
for SSSI after the TOC visit.
Safety. Patients in the dalbavancin arm received a mean of
1.9 active doses during the study. The majority of patients in
the dalbavancin arm (87%) received both active doses (i.e., the
doses given on day 1 and day 8) and were thus considered to
have been exposed to 14 days of treatment. In the linezolid
arm, patients received a mean of 26.2 doses of active medication
(intravenous plus oral medication). Of linezolid recipients, 85%
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days. Adverse events, which were generally mild or moderate
in intensity, were reported by 56% of patients in the dalba-
vancin arm and by 61% in the linezolid arm. Adverse events
that were considered probably or possibly related to treatment
were more frequent in the linezolid arm (32.2%) than in the
dalbavancin arm (25.4%) (table 5). Overall, the type and se-
verity of adverse events were comparable between the treatment
arms. An analysis of duration of adverse events by treatment
arm for which start and stop dates were available demonstrated
that the median duration of adverse events was 1 day shorter
for dalbavancin-treated patients than for comparator-treated
patients; the mean duration of adverse events was similar be-
tween treatment groups. Figure 2 shows a comparison of the
duration of adverse events for dalbavancin-treated patients ver-
sus comparator-treated patients. The incidence of infusion site
reactions was low in both treatment arms (2.8% in the dal-
bavancin arm and 3.9% in the linezolid arm). No cases of red
man syndrome were reported during the study.
A small percentage of patients in each arm (3.9% for the
dalbavancin arm and 3.2% for the linezolid arm) discontinued
treatment because of adverse events. Serious adverse events
were reported by 8% of patients overall (7.5% in the dalba-
vancin arm and 8.5% in the linezolid arm). All but 3 serious
adverse events (1 in the dalbavancin arm and 2 in the linezolid
arm) were considered to be unrelated or unlikely related to
study medication. All 3 treatment-related serious adverse events
pertained to laboratory abnormalities (in the dalbavancin arm,
the adverse event was mild leukopenia, which resolved spon-
taneously; in the linezolid arms, the adverse events were mod-
erate thrombocytopenia, which resolved spontaneously, and se-
vere pancytopenia, which resolved with treatment). Four deaths
occurred during the study (2 in the dalbavancin arm and 2 in
the linezolid arm). All adverse events associated with death were
considered by the investigator to be unrelated or unlikely to
be related to treatment.
Abnormalities in hematological findings and/or clinical
chemistry parameters with potential clinical relevance occurred
infrequently in both treatment arms. Additional examination
of specific abnormalities in the alanine aminotransferase level,
aspartate aminotransferase level, and combined alanine ami-
notransferase and total bilirubin elevations; transitions in he-
patobiliary parameters; and changes in vital signs during the
study did not reveal any areas of clinical concern.
DISCUSSION
The objectives of this study were to determine the efficacy and
the safety of dalbavancin, compared with linezolid, for the treat-
ment of adults with complicated SSSI. The high degree of sus-
tained clinical success reveals that dalbavancin has excellent
clinical efficacy. The data are robust, as indicated by the con-
cordance in success rates for other end points. Figure 1 illus-
trates the similarity in response between dalbavancin treatment
and linezolid treatment for clinical, microbiological, and overall
response at both the EOT visit and the TOC visit, thus con-
ferring clinical relevance to the statistical conclusion of non-
inferiority for the primary end point. The high rates of clinical
success were comparable to published clinical cure rates for
linezolid, oxacillin/dicloxacillin, and flucloxacillin and higher
than published rates for daptomycin, ertapenem, piperacillin-
tazobactam, and quinupristin/dalfopristin [10–15]. Durability
of clinical success was supported by post–TOC visit patient
reports of low rates of antibacterial use and lack of signs or
symptoms of SSSI.
Our study enrolled a population representative of a broad
range of complicated SSSIs. The treatment arms were very well
matched with respect to demographic characteristics and lo-
cation, type, and cause of infection. High rates of pathogen
recovery were achieved at baseline. As expected, S. aureus was
the predominant gram-positive pathogen. The 51% incidence
of MRSA was higher than would be predicted by centralized
epidemiological data from the Centers for Disease Control and
Prevention National Nosocomial Infections Surveillance system
for patients originating from the community (26%) [7].
Recent reports in the medical literature describe an increasing
incidence of community-acquired MRSA infection [16], in-
cluding outbreaks in settings where MRSA represented 150%
of S. aureus isolates [17, 18]. Until recently, community-based
SSSIs that involve MRSA typically occurred in patients with
predisposing risk factors, such as recent hospitalization, contact
with a recently hospitalized individual, or previous antimicro-
bial therapy. However, SSSI due to MRSA is becoming increas-
ingly common in patients without such risk factors, and the
organisms have new characteristics, leading to their designation
as community-acquired MRSA isolates [16, 19, 20]. Environ-
ments and situations in which there is close physical contact
(e.g., sports teams and military recruit training centers) are the
most likely setting for outbreaks of community-acquired MRSA
infection; however, spread of MRSA can also occur in the ab-
sence of physical contact [17, 21]. MRSA infection in ambu-
latory outpatients who develop SSSI is a distinct possibility and
should be considered during treatment selection.
Dalbavancin demonstrated excellent efficacy against MRSA.
The 91% eradication rate exceeds published values for a num-
ber of antibacterials (quinupristin/dalfopristin, ertapenem, lev-
ofloxacin, ticarcillin/clavulanate, and amoxicillin/clavulanate)
[14, 15, 22]. Because it can be administered on an outpatient
basis, dalbavancin may be a reasonable option for empirical
treatment of patients with SSSI that is suspected of involving
MRSA.
Dalbavancin was well tolerated and has a safety profile similar
to that of linezolid. Gastrointestinal events—particularly those
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more prevalent with linezolid therapy. The excellent tolerability
of dalbavancin infusions observed in our study is in contrast
to that of quinupristin/dalfopristin, for which adverse venous
events are common [15]. This low incidence of infusion-related
reactions occurred in a structured environment in which pa-
tients in the dalbavancin arm received more infusions and per-
haps retained indwelling catheters longer than would be oth-
erwise required outside of the context of a clinical study. In an
actual clinical setting, patients would have received only two
30-min infusions of dalbavancin instead of the higher number
of doses they received in the trial because of the double-blind
study design.
Because of the double-blind study design, which was essential
for an unbiased determination of efficacy and safety, the impact
of dalbavancin’s weekly dosing schedule on patient compliance,
hospitalization, or health care costs cannot be ascertained from
our study. It has been demonstrated that treatment with the
intravenous and the 100% bioavailable oral formulations of
linezolid results in a decreased duration of hospitalization and
decreased health care costs for patients with complicated SSSI
known or suspected to involve MRSA [23, 24]. The presence
of MRSA in SSSI has been independently correlated with in-
creased cost [25]. The potential advantages of dalbavancin in
patient acceptance and health outcomes are being examined in
a separate study.
In summary, dalbavancin is well tolerated and highly effective
for the treatment of patients with complicated SSSI, including
infections involving MRSA. Dalbavancin could provide an al-
ternative to vancomycin and linezolid for treatment of SSSIs
due to gram-positive pathogens.
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